VTE acute venous thromboembolism
Posted Thursday 04 February 2010 - 16:37 PM by David Chan
Reference
Comments/Instructions
Dabigatran appears to be a safe and effective alternative to warfarin. However, the drug itself is much more expensive ($400/month for 60 of the 110 mg capsules, which is a lower dose than used in the study, at one Canadian pharmacy's Web site). Some of that increased cost will be ameliorated because international normalized ratio (INR) testing is not needed. Before dabigatran is widely adopted, an appropriate cost-effectiveness analysis must be performed. (LOE = 1b)
Tags
- Cardiovascular
1 comment so far
Brian H.
Sunday 09 October 2011 - 15:43 PM
Short-term study so dabigatran would be suitable for those we would have previously treated for 6-months post VTE. Longer term data are needed for those who have an indication for longer term anticoagulation (this will be the REMEDY trial - data collection finished ~ April 2011).